• ERYtech Pharma, of Lyon, France, received more than $8.65 million from OSEO's Strategic Industrial Innovation program to lead the eight-year TEDAC project, which is focused on developing enzymes targeting chemo- and radio-resistant cancers, as well as tools to identify responders and enable personalized treatment.